Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
A critical look at disease classification/diagnosis criteria in rheumatology.
Journal: Current opinion in immunology
Published: January 14, 2026
Treatment of systemic vasculitis.
Journal: Current opinion in rheumatology
Published: October 10, 2025
Assessing Rheumatoid Arthritis Disease Activity Measures in Ethnic Minority Patients in the United States: Real-World Data From the Ethnic Minority Rheumatoid Arthritis Consortium Registry.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: August 12, 2025
Correspondence on 'Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis' by Nagle et al.
Journal: Annals of the rheumatic diseases
Published: January 18, 2025
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports.
Journal: Rheumatology (Oxford, England)
Published: October 23, 2024
Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial.
Journal: Rheumatology and therapy
Published: July 15, 2024
Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials.
Journal: Rheumatology (Oxford, England)
Published: March 07, 2024
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.
Journal: Clinical and experimental rheumatology
Published: March 05, 2024
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Journal: Clinical and experimental rheumatology
Published: March 03, 2024
Last Updated: 09/26/2026